Profound Medical Corp
TSX:PRN
Profound Medical Corp
TSX:PRN
Price:
11.86 CAD
4.13%
Updated:
May 15, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-7
Current
-7.2
Median
12.9
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-7
Enterprise Value
/
261.6m
EBITDA
-27.5m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| CA |
|
Profound Medical Corp
TSX:PRN
|
289.7m CAD | -7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
181.5B USD | 19 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
139.8B USD | 57.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.1B USD | 24.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.8B USD | 14.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.5B USD | 31.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.8B USD | 18.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.4B EUR | 18.7 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
376.2B CNY | 28.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
53.7B USD | 27.6 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.3B USD | 60 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-7.5
2-Years Forward
EV/EBITDA
-17
3-Years Forward
EV/EBITDA
107.1
You don't have any saved screeners yet
